Cargando…

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment

Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy for the management of solid tumor malignancies. In ovarian cancer, this is in part due to an immunosuppressive cytokine and cellular tumor microenvironment which suppresses adoptively transferred T cells. We engineered an armo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeku, Oladapo O., Purdon, Terence J., Koneru, Mythili, Spriggs, David, Brentjens, Renier J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585170/ https://www.ncbi.nlm.nih.gov/pubmed/28874817 http://dx.doi.org/10.1038/s41598-017-10940-8

Ejemplares similares

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition
por: Yeku, Oladapo O., et al.
Publicado: (2021)

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
por: Rafiq, Sarwish, et al.
Publicado: (2018)

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer
por: Koneru, Mythili, et al.
Publicado: (2015)

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
por: Avanzi, Mauro P., et al.
Publicado: (2018)

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019)

Cytokine IL-36γ Improves CAR T Cell Functionality and Induces Endogenous Anti-Tumor Response
por: Li, Xinghuo, et al.
Publicado: (2020)

IL-24 armored CAR19-T cells show enhanced antitumor activity and persistence
por: Hu, Qian, et al.
Publicado: (2021)

Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages
por: Song, Mei, et al.
Publicado: (2020)

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
por: Shi, Hongtai, et al.
Publicado: (2023)

Toxicity and management in CAR T-cell therapy
por: Bonifant, Challice L, et al.
Publicado: (2016)

CD103(+) cDC1 and endogenous CD8(+) T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function
por: Kuhn, Nicholas F., et al.
Publicado: (2020)

Multipurposing CARs: Same engine, different vehicles
por: Hossian, A.K.M. Nawshad, et al.
Publicado: (2022)

A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma
por: Yeku, Oladapo, et al.
Publicado: (2020)

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
por: Rodriguez-Garcia, Alba, et al.
Publicado: (2020)

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen
por: Rafiq, S, et al.
Publicado: (2016)

Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
por: Hawkins, Elizabeth R, et al.
Publicado: (2021)

Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer
por: Henze, Janina, et al.
Publicado: (2020)

A Panorama of Immune Fighters Armored with CARs in Acute Myeloid Leukemia
por: Christodoulou, Ilias, et al.
Publicado: (2023)

How do CARs work?: Early insights from recent clinical studies targeting CD19
por: Davila, Marco L., et al.
Publicado: (2012)

Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer
por: Zanvit, Peter, et al.
Publicado: (2023)

Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells
por: Dixon, Brianne N., et al.
Publicado: (2020)

GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells
por: Liu, Enli, et al.
Publicado: (2021)

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
por: Bachiller, Mireia, et al.
Publicado: (2021)

Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors
por: Wang, Yufeng, et al.
Publicado: (2023)

Weapons & armor
Publicado: (1978)

Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia
por: Jin, Chun-Hui, et al.
Publicado: (2018)

Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
por: Alabanza, Leah M., et al.
Publicado: (2022)

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
por: Suryadevara, Carter M., et al.
Publicado: (2018)

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
por: Rodriguez-Marquez, Paula, et al.
Publicado: (2022)

Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
por: Wang, Yue, et al.
Publicado: (2023)

IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
por: Jaspers, Janneke E., et al.
Publicado: (2023)

Radium-223 and concomitant therapies: prospects and prudence
por: Yeku, Oladapo, et al.
Publicado: (2016)

Targeting the tumor microenvironment to enhance antitumor immune responses
por: Van der Jeught, Kevin, et al.
Publicado: (2014)

Tumor immune microenvironment (TIME) to enhance antitumor immunity
por: Rajbhandary, Sajin, et al.
Publicado: (2023)

Negligible heat strain in armored vehicle officers wearing personal body armor
por: Stewart, Ian B, et al.
Publicado: (2011)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies
por: Stasenko, Marina, et al.
Publicado: (2021)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

Incorporation of functional elements enhances the antitumor capacity of CAR T cells
por: Qin, Le, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4iu71p33l4vvvjl46imhc312ob